148 related articles for article (PubMed ID: 33843984)
1. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.
Shaffer BC; Le Luduec JB; Park S; Devlin S; Archer A; Davis E; Cooper C; Nhaissi M; Suri B; Wells D; Tamari R; Papadopoulos E; Jakubowski AA; Giralt S; Hsu KC
Blood Adv; 2021 Apr; 5(7):2003-2011. PubMed ID: 33843984
[TBL] [Abstract][Full Text] [Related]
2. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
[TBL] [Abstract][Full Text] [Related]
3. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
[TBL] [Abstract][Full Text] [Related]
4. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
5. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
[TBL] [Abstract][Full Text] [Related]
6. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
[TBL] [Abstract][Full Text] [Related]
7. Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
Sobecks RM; Wang T; Askar M; Gallagher MM; Haagenson M; Spellman S; Fernandez-Vina M; Malmberg KJ; Müller C; Battiwalla M; Gajewski J; Verneris MR; Ringdén O; Marino S; Davies S; Dehn J; Bornhäuser M; Inamoto Y; Woolfrey A; Shaw P; Pollack M; Weisdorf D; Milller J; Hurley C; Lee SJ; Hsu K
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1589-96. PubMed ID: 25960307
[TBL] [Abstract][Full Text] [Related]
8. HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation.
van der Ploeg K; Le Luduec JB; Stevenson PA; Park S; Gooley TA; Petersdorf EW; Shaffer BC; Hsu KC
Blood Adv; 2020 Oct; 4(19):4955-4964. PubMed ID: 33049053
[TBL] [Abstract][Full Text] [Related]
9. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
[TBL] [Abstract][Full Text] [Related]
10. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
11. Donor Killer Immunoglobulin-Like Receptor Profile Bx1 Imparts a Negative Effect and Centromeric B-Specific Gene Motifs Render a Positive Effect on Standard-Risk Acute Myeloid Leukemia/Myelodysplastic Syndrome Patient Survival after Unrelated Donor Hematopoietic Stem Cell Transplantation.
Bao X; Wang M; Zhou H; Zhang H; Wu X; Yuan X; Li Y; Wu D; He J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):232-239. PubMed ID: 26371372
[TBL] [Abstract][Full Text] [Related]
12. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
[TBL] [Abstract][Full Text] [Related]
13. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
Fein JA; Shouval R; Krieger E; Spellman SR; Wang T; Baldauf H; Fleischhauer K; Kröger N; Horowitz M; Maiers M; Miller JS; Mohty M; Nagler A; Weisdorf D; Malmberg KJ; Toor AA; Schetelig J; Romee R; Koreth J
Blood Adv; 2024 Feb; 8(3):581-590. PubMed ID: 38052043
[TBL] [Abstract][Full Text] [Related]
14. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
15. Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML.
Krieger E; Qayyum R; Keating A; Toor A
Bone Marrow Transplant; 2021 Nov; 56(11):2714-2722. PubMed ID: 34234295
[TBL] [Abstract][Full Text] [Related]
16. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
Weisdorf D; Cooley S; Wang T; Trachtenberg E; Vierra-Green C; Spellman S; Sees JA; Spahn A; Vogel J; Fehniger TA; Woolfrey AE; Devine SM; Ross M; Waller EK; Sobecks RM; McGuirk J; Oran B; Farag SS; Shore T; Van Besien K; Marsh SGE; Guethlein LA; Parham P; Miller JS
Blood Adv; 2020 Feb; 4(4):740-754. PubMed ID: 32092137
[TBL] [Abstract][Full Text] [Related]
17. KIR Donor Selection: Feasibility in Identifying better Donors.
Weisdorf D; Cooley S; Wang T; Trachtenberg E; Haagenson MD; Vierra-Green C; Spellman S; Spahn A; Vogel J; Kobusingye H; Fehninger T; Woolfrey A; Devine S; Ross M; Waller EK; Sobecks R; Parham P; Guethlein LA; Marsh SGE; Miller J;
Biol Blood Marrow Transplant; 2019 Jan; 25(1):e28-e32. PubMed ID: 30149149
[TBL] [Abstract][Full Text] [Related]
18. Donor
Schetelig J; Baldauf H; Heidenreich F; Hoogenboom JD; Spellman SR; Kulagin A; Schroeder T; Sengeloev H; Dreger P; Forcade E; Vydra J; Wagner-Drouet EM; Choi G; Paneesha S; Miranda NAA; Tanase A; de Wreede LC; Lange V; Schmidt AH; Sauter J; Fein JA; Bolon YT; He M; Marsh SGE; Gadalla SM; Paczesny S; Ruggeri A; Chabannon C; Fleischhauer K
Front Immunol; 2024; 15():1350470. PubMed ID: 38629074
[TBL] [Abstract][Full Text] [Related]
19. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.
Cooley S; Weisdorf DJ; Guethlein LA; Klein JP; Wang T; Marsh SG; Spellman S; Haagenson MD; Saeturn K; Ladner M; Trachtenberg E; Parham P; Miller JS
J Immunol; 2014 May; 192(10):4592-600. PubMed ID: 24748496
[TBL] [Abstract][Full Text] [Related]
20. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]